Conteville

Bile duct cancer is a rare and diverse group of tumors that generally have a poor outlook. Surgery is currently the only curative option for localized disease, while chemotherapy is the standard treatment for advanced cases. This study aims to identify markers that can predict how patients will respond to treatments such as surgery, chemotherapy, targeted therapy, and local treatments, as well as to evaluate the effectiveness and tolerance of these treatments in everyday clinical practice. It includes patients diagnosed between 2003 and 2030 and follows their progress for up to 10 years from the initial cancer diagnosis. The study is a multi-center cohort design that involves both retrospective and prospective data collection. Patients diagnosed or operated on more than 10 years ago will have retrospective follow-up data, while those diagnosed within the last 10 years or in the future up to 2030 will have retro-prospective follow-up. The study collects detailed information on treatments received and patient outcomes to better understand prognosis and guide future therapy decisions. Participants will have data collected from their medical history, treatments, and outcomes throughout the study period. Researchers will monitor survival rates, particularly focusing on patients with advanced bile duct cancer who survive less than 6 months. Data collected can also support educational projects such as doctoral theses. The total duration of follow-up may last up to 10 years from diagnosis, with ongoing review by the study committee and sponsor to ensure data quality and compliance.

Researchers are studying the levels of serum Neurofilament-light chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) as potential markers of disease activity and progression in people with Multiple Sclerosis (MS). The study aims to understand how these biomarkers vary at different stages and important points in the disease course. The investigation includes patients with MS who are part of the OFSEP cohort, which tracks the disease over time. Participants will provide blood samples collected in 2 tubes of 4 ml each. These samples will be tested to measure the levels of NfL and GFAP. The study includes patients with both stable and active forms of MS, identified by clinical relapse, disability progression, or MRI activity. Different groups are studied depending on the disease status and participation in specific centers within the OFSEP cohort. During the study, researchers will monitor the serum NfL and GFAP levels at multiple time points, including inclusion, 6 months, 12 months, 18 months, 2 years, and up to 6 years. This long-term follow-up will help assess changes in these biomarkers over time. The study also collects clinical information such as the Expanded Disability Status Scale (EDSS) scores and treatment status. Outcomes focus on comparing biomarker levels between patients with evolving versus stable disease to better understand MS progression.